PTC Therapeutics Inc [PTCT] stock is trading at $40.75, down -1.57%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The PTCT shares have gain 4.22% over the last week, with a monthly amount glided 8.20%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Robert W. Baird started tracking the stock with Outperform rating on September 04, 2024, and set its price target to $44. Raymond James upgraded its rating to a Mkt Perform. Morgan Stanley downgraded its rating to a Underweight but $28 remained the price target by the analyst firm on December 19, 2023. Wells Fargo started tracking with a Overweight rating for this stock on December 08, 2023, and assigned it a price target of $37. In a note dated October 30, 2023, Oppenheimer upgraded an Outperform rating on this stock but restated the target price of $165.
PTC Therapeutics Inc [PTCT] stock has fluctuated between $17.53 and $43.40 over the past year. Currently, Wall Street analysts expect the stock to reach $46.5 within the next 12 months. PTC Therapeutics Inc [NASDAQ: PTCT] shares were valued at $40.75 at the most recent close of the market. An investor can expect a potential return of 14.11% based on the average PTCT price forecast.
Analyzing the PTCT fundamentals
PTC Therapeutics Inc [NASDAQ:PTCT] reported sales of 900.45M for the trailing twelve months, which represents a drop of -12.68%. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.55%, and Net Profit Margin reading is -0.53%. To continue investigating profitability, this company’s Return on Assets is posted at -0.25, Equity is 0.57 and Total Capital is -0.15. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.31.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 40.22 points at the first support level, and at 39.68 for the second support level. However, for the 1st resistance point, the stock is sitting at 41.66, and for the 2nd resistance point, it is at 42.57.
Ratios To Look Out For
For context, PTC Therapeutics Inc’s Current Ratio is 2.23. Also, the Quick Ratio is 2.17, while the Cash Ratio stands at 1.07. Considering the valuation of this stock, the price to sales ratio is 3.48.
Transactions by insiders
Recent insider trading involved Gravier Pierre, CHIEF FINANCIAL OFFICER, that happened on Jul 16 ’24 when 2269.0 shares were sold. Director, ZELDIS JEROME B completed a deal on May 22 ’24 to sell 20000.0 shares. Meanwhile, EVP & CHIEF MEDICAL OFFICER Golden Lee Scott sold 175.0 shares on May 07 ’24.
